Seer Insights Program
Accelerate development decisions with deep, unbiased proteomics
Seer collaborates with industry partners to support development-stage proteomics programs through the Seer Insights Development Access Program. Partners receive access to Seer’s Proteograph® workflow to generate proteomic insights that inform development-stage programs.
This program is designed to support studies that address key biological questions relevant to drug development, including:
- Target validation
- Mechanism of action
- Resistance biology
- Biomarker discovery
- Patient stratification
Selected participants will receive support through Seer’s Technology Access Center (STAC), including mass spectrometry analysis and bioinformatics support.
What to expect
Biopharma teams are invited to submit a brief development concept describing how proteomic analysis could inform a development-stage program.
Submissions require approximately 10 minutes to complete, and optional supporting materials may be uploaded.
Projects will undergo an initial eligibility and feasibility review, and applicants will typically receive feedback within 10 days of submission.
Eligible submissions will be included in the final program review, which will occur after the submission deadline.
Up to three development programs will be selected for participation in the 2026 program.
Participation may remain confidential, unless otherwise agreed.
Program collaboration & support
Selected teams will collaborate with Seer scientists to generate deep proteomic insight relevant to their development-stage program.
Support provided through the STAC includes:
- Access to Seer’s Proteograph® workflow for unbiased proteomic profiling
- Processing and analysis of up to 160 samples through the Proteograph platform
- State-of-the-art mass spectrometry analysis performed at STAC
- Bioinformatics support for study analysis and data interpretation
- Ongoing scientific engagement with Seer proteomics experts to support study execution and interpretation
Support is structured to enable a well-defined study addressing the development question described in the submitted concept.
2026 Program Timeline
- April 19, 2026 Submissions open
- Within 10 days of submission Initial eligibility feedback
- June 12, 2026 Submission deadline
Final program selections will be made after the submission deadline.
Seer reserves the right to restrict access to fewer than three programs if submissions do not meet program criteria.
Frequently Asked Questions
Who is eligible to apply for the Development Access Program?
This track is open to biotechnology and pharmaceutical teams advancing development-stage programs. Submissions should describe how proteomic analysis could inform a development decision, such as target validation, mechanism of action, resistance biology, or biomarker strategy.
The Seer Insights program is designed for researchers and development teams who do not have established in-house mass spectrometry-based proteomics capabilities and are seeking to incorporate deep proteomic analysis into their work.
Please review the Official Rules for more information.
What information is required for submission?
Applicants are asked to provide a short concept describing:
- The development-stage program or biological question
- How proteomic analysis could inform development decisions
- Basic study feasibility details such as sample type and availability
Optional supporting materials (e.g., a short concept deck or study overview) may also be provided.
The submission process typically requires approximately 10 minutes to complete.
What happens after I submit a concept?
Submissions will undergo an initial review to confirm program eligibility and study feasibility.
Applicants will typically receive feedback within 10 days of submission indicating whether the concept:
- Is eligible for final review
- Requires additional information
- Is not aligned with the current program scope
Eligible submissions will move forward to the final program review stage.
When are final selections made?
Final selections will be made after the submission deadline in June 2026.
Up to three development programs will be selected to participate in the program.
Seer reserves the right to select fewer than three projects if submissions do not meet program criteria.
What are the selection criteria?
Proposals are evaluated by scientific leaders from academia and industry, including members of Seer’s Scientific Advisory Board. Criteria include:
- Relevance of proposed study to address a biologically meaning question for therapeutic discovery or development
- Potential impact to inform development decisions or advance biological understanding of therapeutic program
- Clarity and practicality of the overall study plan
- Alignment with Proteograph workflow capabilities
Is participation confidential?
Yes. Participation may remain confidential. Selected participants are not required to publicly disclose their involvement unless mutually agreed.
Who owns the resulting data and intellectual property?
All generated data and resulting intellectual property remain with the participating organization, subject to the applicable STAC terms and conditions.
Are selected participants required to publicly present their findings?
No. Public presentations or case studies are optional and will only occur if mutually agreed upon by Seer and the participant.
Can I discuss my concept with Seer before submitting?
Yes. Teams are welcome to contact Seer to discuss potential program fit prior to submission.